{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:38:18Z","timestamp":1788305898907,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms\/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients receiving 5-alpha reductase inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This non-interventional, cross-sectional study collected data from urologists in Spain <jats:italic>(N<\/jats:italic>\u2009=\u2009100) and Brazil <jats:italic>(N<\/jats:italic>\u2009=\u2009100) via a self-reporting questionnaire and patient record forms. Endpoints included: frequency\/methodology of prostate-specific antigen monitoring, concerns about the effect of 5-alpha reductase inhibitors on prostate-specific antigen monitoring, triggers of prostate biopsy, and concerns when switching 5-alpha reductase inhibitor formulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Over half of urologists monitored prostate-specific antigen every 6\u00a0months (Spain 59%, Brazil 58%). Preferred methods were the <jats:italic>\u201cdoubling rule\u201d<\/jats:italic> (Spain 66%, Brazil 41%) and <jats:italic>\u201cincrease from nadir\u201d<\/jats:italic> (Spain 28%, Brazil 43%). A minority of urologists monitored unadjusted values (Spain 3%, Brazil 11%) or did not monitor prostate-specific antigen (Spain 1%, Brazil 3%). Most urologists ranked the potential for 5-alpha reductase inhibitors to mask prostate cancer as their top concern (Spain 65%, Brazil 56%). The most selected trigger for prostate biopsy was <jats:italic>\u201cif doubled (adjusted) prostate-specific antigen level after 6\u00a0months of treatment is<\/jats:italic>\u2009&gt;\u2009<jats:italic>4\u00a0ng\/mL\u201d<\/jats:italic> (Spain 39%, Brazil 37%). Many urologists were moderately\/very concerned about the effect on prostate-specific antigen when switching 5-alpha reductase inhibitor formulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>An unmet need exists for standard guidance and continuous education to support optimal monitoring and interpretation of prostate-specific antigen in patients with lower urinary tract symptoms\/benign prostate enlargement treated with 5-alpha reductase inhibitors.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12894-025-01701-1","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:22:33Z","timestamp":1738333353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil"],"prefix":"10.1186","volume":"25","author":[{"given":"Juan Manuel","family":"Palacios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiksha","family":"Kapse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Augusto","family":"Averbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Budia","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryakant","family":"Somvanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Souza Lima","family":"da Costa Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"1701_CR1","unstructured":"Aurobindo Pharma - Milpharm Ltd. Summary of product characterisics: dutasteride\/tamsulosin hydrochloride 0.5 mg\/0.4 mg capsules, hard. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/11304\/smpc#gref. Accessed 28 May 2024."},{"key":"1701_CR2","unstructured":"Aurobindo Pharma - Milpharm Ltd. Summary of product characteristics: finasteride 5mg tablets. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/547\/smpc#gref. Accessed 13 Nov 2023."},{"key":"1701_CR3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1464-410X.2011.10373.x","volume":"109","author":"M Marberger","year":"2012","unstructured":"Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012;109:1162\u20139.","journal-title":"BJU Int"},{"key":"1701_CR4","unstructured":"Rivopharm Uk Ltd. Summary of product characteristics: dutasteride 0.5mg capsules, soft. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/8988\/smpc#gref. Accessed 13 Nov 2023."},{"key":"1701_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD Mcconnell","year":"2003","unstructured":"Mcconnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387\u201398.","journal-title":"N Engl J Med"},{"key":"1701_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","volume":"179","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616\u201321.","journal-title":"J Urol"},{"key":"1701_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123\u201331.","journal-title":"Eur Urol"},{"key":"1701_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, Mcvary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. 2021;206:806\u201317.","journal-title":"J Urol"},{"key":"1701_CR9","unstructured":"Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2023. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2023.pdf. Accessed 28 May 2024."},{"key":"1701_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","volume":"190","author":"HB Carter","year":"2013","unstructured":"Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419\u201326.","journal-title":"J Urol"},{"key":"1701_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, Van Den Bergh RCN, Briers E, Van Den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362.","journal-title":"Eur Urol."},{"key":"1701_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.mcna.2020.08.007","volume":"104","author":"SV Carlsson","year":"2020","unstructured":"Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am. 2020;104:1051\u201362.","journal-title":"Med Clin North Am"},{"key":"1701_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","volume":"179","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, Mckay RR, et al. Association of treatment with 5\u03b1-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179:812\u20139.","journal-title":"JAMA Intern Med"},{"key":"1701_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.juro.2010.03.020","volume":"184","author":"BT Helfand","year":"2010","unstructured":"Helfand BT, Blackwell RH, Mcvary KT. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. J Urol. 2010;184:218\u201323.","journal-title":"J Urol"},{"key":"1701_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0022-5347(01)63760-1","volume":"159","author":"JA Chicharro-Molero","year":"1998","unstructured":"Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ, Del Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol. 1998;159:878\u201382.","journal-title":"J Urol"},{"key":"1701_CR16","doi-asserted-by":"publisher","first-page":"e72953102","DOI":"10.33448\/rsd-v9i5.3102","volume":"9","author":"CG Tier","year":"2020","unstructured":"Tier CG, Recart RH, Lana LD, Simon BS, Garcia RP, Furtado BG. Prevalence of prostatic changes in the elderly. Research, Society and Development. 2020;9:e72953102.","journal-title":"Research, Society and Development"},{"key":"1701_CR17","first-page":"21","volume":"15 Suppl 1","author":"J Barkin","year":"2008","unstructured":"Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. Can J Urol. 2008;15 Suppl 1:21\u201330; discussion.","journal-title":"Can J Urol."},{"key":"1701_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.acuro.2023.11.006","volume":"48","author":"J Navarro-P\u00e9rez","year":"2024","unstructured":"Navarro-P\u00e9rez J, L\u00f3pez Alcina E, Calabiug P\u00e9rez J, Brotons Munt\u00f3 F, Mart\u00ednez A, Vallejo L, et al. Changes in benign prostatic hyperplasia management in Valencia: a real-world evidence analysis. Actas Urol Esp (Engl Ed). 2024;48:461\u20139.","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"1701_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1590\/s1677-5538.ibju.2020.03.02","volume":"46","author":"WFSJ Busato","year":"2020","unstructured":"Busato WFSJ. Use of 5\u03b1-reductase inhibitor and delay in prostate cancer diagnosis and treatment. Int Braz J Urol. 2020;46:456\u20138.","journal-title":"Int Braz J Urol"},{"key":"1701_CR20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192\u2013202.","journal-title":"N Engl J Med"},{"key":"1701_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/j.1742-1241.2008.01785.x","volume":"62","author":"M Emberton","year":"2008","unstructured":"Emberton M, Cornel EB, Bassi PF, Fourcade RO, G\u00f3mez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62:1076\u201386.","journal-title":"Int J Clin Pract"},{"key":"1701_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","volume":"8","author":"L Bj\u00f6rnebo","year":"2022","unstructured":"Bj\u00f6rnebo L, Nordstr\u00f6m T, Discacciati A, Palsdottir T, Aly M, Gr\u00f6nberg H, et al. Association of 5\u03b1-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022;8:1019\u201326.","journal-title":"JAMA Oncol"},{"key":"1701_CR23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0022-5347(05)00984-5","volume":"175","author":"GL Andriole","year":"2006","unstructured":"Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol. 2006;175:1657\u201362.","journal-title":"J Urol"},{"key":"1701_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/iju.14590","volume":"28","author":"T Inoue","year":"2021","unstructured":"Inoue T, Yoshimura K, Terada N, Tsukino H, Murota T, Kinoshita H, et al. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study). Int J Urol. 2021;28:849\u201354.","journal-title":"Int J Urol"},{"key":"1701_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.juro.2006.04.024","volume":"176","author":"LS Marks","year":"2006","unstructured":"Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176:868\u201374.","journal-title":"J Urol"},{"key":"1701_CR26","unstructured":"Merck & Co. Inc. US prescribing information: PROPECIA\u00ae (finasteride) tablets for oral use. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020788s020s021s023lbl.pdf. Accessed 13 Nov 2023."},{"key":"1701_CR27","unstructured":"Glaxosmithkline. US prescribing information: AVODART (dutasteride) soft gelatin capsules. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021319s023s025lbl.pdf. Accessed 13 Nov 2023."},{"key":"1701_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/jnci\/djj307","volume":"98","author":"IM Thompson","year":"2006","unstructured":"Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128\u201333.","journal-title":"J Natl Cancer Inst"},{"key":"1701_CR29","doi-asserted-by":"publisher","first-page":"e13810","DOI":"10.1111\/and.13810","volume":"52","author":"D Obinata","year":"2020","unstructured":"Obinata D, Suzuki S, Yamanaka Y, Yoshizawa T, Mochida J, Yamaguchi K, et al. Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: a retrospective study. Andrologia. 2020;52:e13810.","journal-title":"Andrologia"},{"key":"1701_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamaoncol.2015.0387","volume":"1","author":"L Azoulay","year":"2015","unstructured":"Azoulay L, Eberg M, Benayoun S, Pollak M. 5\u03b1-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol. 2015;1:314\u201320.","journal-title":"JAMA Oncol"},{"key":"1701_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2014.1600","volume":"174","author":"MA Preston","year":"2014","unstructured":"Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5\u03b1-reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174:1301\u20137.","journal-title":"JAMA Intern Med"},{"key":"1701_CR32","doi-asserted-by":"publisher","first-page":"f3406","DOI":"10.1136\/bmj.f3406","volume":"346","author":"D Robinson","year":"2013","unstructured":"Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5\u03b1-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406.","journal-title":"BMJ"},{"key":"1701_CR33","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jnci\/djy036","volume":"110","author":"A Wallerstedt","year":"2018","unstructured":"Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M. Risk of prostate cancer in men treated with 5\u03b1-reductase inhibitors - a large population-based prospective study. J Natl Cancer Inst. 2018;110:1216\u201321.","journal-title":"J Natl Cancer Inst"},{"key":"1701_CR34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.mayocp.2016.07.023","volume":"91","author":"LP Wallner","year":"2016","unstructured":"Wallner LP, Dibello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, et al. 5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia. Mayo Clin Proc. 2016;91:1717\u201326.","journal-title":"Mayo Clin Proc"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01701-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01701-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:22:44Z","timestamp":1738333364000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01701-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01701-1","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A central independent review board (Pearl Independent Institution Review Board) considered that the research had no risk or minimal risk to participants and was exempt from most of the requirements of the Federal Policy for the Protection of Human Subjects. Written informed consent was obtained from all participants. This study was conducted according to the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study complied with all applicable laws in the relevant countries regarding participant privacy. Urologists completed consent forms before study participation. All patient data were de-identified so informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMP, PK, VC and SS are employed by and hold financial equities in GSK. MAA, ABA, DSLdCC and FP declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}